Loading company…
Suzhou Maoxing Biotechnology develops CAR-T therapies focused on brain tumors.
Founded in 2017 and based in Suzhou, Suzhou Maoxing Biotechnology develops chimeric antigen receptor T-cell (CAR-T) therapies, with a focus on brain tumors. Its technology is intended to address graft-versus-host and host-versus-graft disease and support long-term survival in patients.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in